Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.10USD
11 Dec 2017
Change (% chg)

$0.00 (+0.46%)
Prev Close
$1.10
Open
$1.11
Day's High
$1.13
Day's Low
$1.09
Volume
122,578
Avg. Vol
62,953
52-wk High
$1.38
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Bioline Rx Ltd ::BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML.BIOLINE RX-RESULTS SHOW THAT COMBINATION OF BL-8040 WITH HIGH-DOSE ARA-C SIGNIFICANTLY IMPROVED OVERALL SURVIVAL VERSUS HISTORICAL DATA OF HIDAC MONOTHERAPY.  Full Article

BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - BioLine Rx Ltd :BioLineRx reports third quarter 2017 financial results.BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​.  Full Article

BioLine RX says ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - BioLine RX Ltd :BioLine RX Ltd - ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 million - SEC filing.  Full Article

BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Bioline Rx Ltd :BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration.Bioline RX Ltd - ‍Genentech commenced a phase 1b/2 study for treatment of gastric cancer with BL-8040 in combination with atezolizumab​.  Full Article

BioLine, I-Bridge Capital establish new drug development JV in China
Thursday, 25 Aug 2016 

Bioline RX: Bioline RX and I-Bridge Capital establish a new drug development joint venture in china .Under terms of JV agreement, each partner will provide seed capital of one million dollars to venture.  Full Article

Bioline RX Ltd Q2 loss per share $0.07
Thursday, 11 Aug 2016 

Bioline Rx Ltd : Biolinerx reports second quarter 2016 financial results .Qtrly loss per share $0.07.  Full Article

Biolinerx signs second clinical immuno-oncology collaboration agreement
Monday, 8 Aug 2016 

Bioline RX LTD :Biolinerx signs second clinical immuno-oncology collaboration agreement to investigate combination of bl-8040 and Keytruda® for pancreatic cancer.  Full Article

BioLineRx reports net loss for Q1 of $3.5 mln
Tuesday, 17 May 2016 

BioLineRx Ltd: BioLineRx reports first quarter 2016 financial results .Net loss for three months ended March 31, 2016 amounted to $3.5 million , compared with a net loss of $4.3 million.  Full Article

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML